Compare AANJANEYA LIFECARE with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS CADILA HEALTHCARE DR. DATSONS LABS/
CADILA HEALTHCARE
 
P/E (TTM) x -10.9 28.3 - View Chart
P/BV x 0.2 4.6 3.6% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 DR. DATSONS LABS   CADILA HEALTHCARE
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
CADILA HEALTHCARE
Mar-20
DR. DATSONS LABS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs126352 35.7%   
Low Rs31207 15.0%   
Sales per share (Unadj.) Rs133.0139.2 95.5%  
Earnings per share (Unadj.) Rs0.211.8 1.3%  
Cash flow per share (Unadj.) Rs6.618.6 35.6%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs128.8101.4 127.1%  
Shares outstanding (eoy) m31.661,023.74 3.1%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.62.0 29.3%   
Avg P/E ratio x516.123.7 2,173.2%  
P/CF ratio (eoy) x11.815.0 78.7%  
Price / Book Value ratio x0.62.8 22.0%  
Dividend payout %029.8 0.0%   
Avg Mkt Cap Rs m2,477286,033 0.9%   
No. of employees `000NA13.4 0.0%   
Total wages/salary Rs m5624,145 0.2%   
Avg. sales/employee Rs ThNM10,632.7-  
Avg. wages/employee Rs ThNM1,801.2-  
Avg. net profit/employee Rs ThNM898.5-  
INCOME DATA
Net Sales Rs m4,211142,531 3.0%  
Other income Rs m791,139 6.9%   
Total revenues Rs m4,289143,670 3.0%   
Gross profit Rs m56924,198 2.3%  
Depreciation Rs m2046,965 2.9%   
Interest Rs m4303,418 12.6%   
Profit before tax Rs m1314,954 0.1%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m63,198 0.2%   
Profit after tax Rs m512,044 0.0%  
Gross profit margin %13.517.0 79.5%  
Effective tax rate %48.021.4 224.6%   
Net profit margin %0.18.5 1.3%  
BALANCE SHEET DATA
Current assets Rs m6,85287,154 7.9%   
Current liabilities Rs m6,71182,694 8.1%   
Net working cap to sales %3.33.1 107.0%  
Current ratio x1.01.1 96.9%  
Inventory Days Days16171 225.2%  
Debtors Days Days31894 339.5%  
Net fixed assets Rs m3,673133,236 2.8%   
Share capital Rs m3171,024 30.9%   
"Free" reserves Rs m3,761102,733 3.7%   
Net worth Rs m4,078103,757 3.9%   
Long term debt Rs m1,67132,146 5.2%   
Total assets Rs m12,633236,866 5.3%  
Interest coverage x1.05.4 19.2%   
Debt to equity ratio x0.40.3 132.3%  
Sales to assets ratio x0.30.6 55.4%   
Return on assets %3.46.5 52.8%  
Return on equity %0.111.6 1.0%  
Return on capital %7.713.7 55.9%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96452,752 1.8%   
Fx outflow Rs m60714,504 4.2%   
Net fx Rs m35738,248 0.9%   
CASH FLOW
From Operations Rs m1,34525,054 5.4%  
From Investments Rs m-2,256-10,123 22.3%  
From Financial Activity Rs m-1,200-10,942 11.0%  
Net Cashflow Rs m-2,1113,989 -52.9%  

Share Holding

Indian Promoters % 4.5 74.8 6.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.3 -  
FIIs % 1.4 5.9 22.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 11.0 855.5%  
Shareholders   20,807 44,069 47.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   UNICHEM LAB  AUROBINDO PHARMA  STERLING BIOTECH  GLENMARK PHARMA  VENUS REMEDIES  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 101 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading up by 357 points, up 0.7% at 49,267 levels.

Related Views on News

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS